Destiny Pharma
Ticker: DEST Exchange: AIM

Destiny Pharma is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.

C. difficile expert insight - in discussion with Professor Gerding

Professor Dale Gerding is an expert on therapy for C.difficile whose work was recently recognised with a Lifetime Achievement award from the C Diff Foundation. Over the course of a detailed interview with Dr Andy Smith (analyst and microbiologist), Professor Gerding shares his latest thoughts on the growing threat posed by C diff. He also discusses the merits in its treatment shown by NTCD-M3, being developed by AIM-listed Destiny Pharma plc where Dale is a member of the Scientific Advisory Board.

You can watch the full video below (approximate length 43 minutes), divided into chapters for ease of viewing:

0:00     Introduction
0:51     History of CDIs
6:09    Clinical & commercial significance
11:51    Importance of the microbiome
17:53   Current / ideal standard of care
24:58  M3’s advantages over competition
29:01   Q&A

26810392321 - destiny-pharma
Return to Destiny Pharma

Register to be first

Get research on the companies that interest you straight to your inbox

Register For Updates